Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia

Cancer. 2009; 115(20):4839-48

View abstract

Authors

Heaney M, Toy E,  Vekeman F,  Laliberte F, Dority B, Perlman D, Barghout V,  Duh M